23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › LYELL IMMUNOPHARMA INC. › 2023-2024

LYELL IMMUNOPHARMA INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and LYELL IMMUNOPHARMA INC.’s Form 8-K, filed June 14, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 138Asset managers, any item
  • 683Fund votes
  • June 14, 2024Meeting date

Results at a glance

Meeting of June 14, 2024: 4 items on LYELL IMMUNOPHARMA INC.’s Form 8-K, filed June 14, 2024: 4 passed (calculated).

Dissent

Significant dissent: 1 say-on-pay vote (69.8% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore LYELL IMMUNOPHARMA INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by LYELL IMMUNOPHARMA INC.

These tallies are LYELL IMMUNOPHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 14, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

LYELL IMMUNOPHARMA INC. — official shareholder meeting results, meeting held June 14, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Elizabeth Nabel, M.D. 147,841,830---- 16,168,96434,804,776 90%Passed (calculated)—
Elect Director: Lynn Seely, M.D. 150,085,827---- 13,924,96734,804,776 92%Passed (calculated)—
2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. 198,604,866153,72756,977 ---- 99.9%Passed (calculated)—
3. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. 108,778,03646,997,7368,235,022 --34,804,776 70%Passed (calculated)—

Source: LYELL IMMUNOPHARMA INC., Form 8-K, filed with the SEC on June 14, 2024 — read the filing on EDGAR.

How asset managers voted at the LYELL IMMUNOPHARMA INC. 2023-2024 meeting

138 asset managers disclosed a vote on at least one LYELL IMMUNOPHARMA INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Elizabeth Nabel, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 147,841,830WITHHELD: 16,168,964
Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: Election of Class III Directors: Elizabeth Nabel, M.D.

LYELL IMMUNOPHARMA INC.’s own tally for this item (“Elect Director: Elizabeth Nabel, M.D.”): 147,841,830 for, 16,168,964 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 24,885,226 for, 6,247,119 withheld.

FORWITHHOLD
FOR: 24,885,226WITHHOLD: 6,247,119
Largest asset managers voting on “Election of Class III Directors: Elizabeth Nabel, M.D.” at LYELL IMMUNOPHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard11,065,2560 00For
T. Rowe Price5,549,5520 00For
BlackRock4,607,0870 00For
Fidelity61,2220 03,440,456Withhold
MFS00 01,469,278Withhold
Charles Schwab1,280,6120 00For
NORTHERN LIGHTS FUND TRUST II801,0160 00For
QUANTITATIVE MASTER SERIES LLC334,3940 00For
John Hancock234,7290 070,870Mixed
Equitable72,2620 0174,830Mixed
Lincoln Financial143,9000 083,215Mixed
Global X221,5970 00For
Invesco00 0167,700Withhold
Nushares ETF Trust00 0156,675Withhold
Pacific Life69,2750 082,998Mixed
ETF Series Solutions00 0129,875Withhold
SEI129,8360 00For
New York Life00 0112,211Withhold
TARGET PORTFOLIO TRUST87,7000 00For
American Century00 081,594Withhold
Bridge Builder Trust73,6260 00For
Voya00 058,585Withhold
Managed Portfolio Series47,7630 00For
ProShares00 044,862Withhold
ETFis Series Trust I00 042,892Withhold

Showing the 25 largest of 46 asset managers. All 46 are in the interactive database (link above).

Elect Director: Lynn Seely, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 150,085,827WITHHELD: 13,924,967
Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: Election of Class III Directors: Lynn Seely, M.D.

LYELL IMMUNOPHARMA INC.’s own tally for this item (“Elect Director: Lynn Seely, M.D.”): 150,085,827 for, 13,924,967 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 26,842,567 for, 4,289,778 withheld.

FOR
FOR: 26,842,567WITHHOLD: 4,289,778
Largest asset managers voting on “Election of Class III Directors: Lynn Seely, M.D.” at LYELL IMMUNOPHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard11,065,2560 00For
T. Rowe Price5,549,5520 00For
BlackRock4,607,0870 00For
Fidelity61,2220 03,440,456Withhold
MFS1,469,2780 00For
Charles Schwab1,280,6120 00For
NORTHERN LIGHTS FUND TRUST II801,0160 00For
QUANTITATIVE MASTER SERIES LLC334,3940 00For
John Hancock234,7290 070,870Mixed
Equitable247,0920 00For
Lincoln Financial143,9000 083,215Mixed
Global X221,5970 00For
Invesco167,7000 00For
Nushares ETF Trust00 0156,675Withhold
Pacific Life152,2730 00For
ETF Series Solutions00 0129,875Withhold
SEI129,8360 00For
New York Life00 0112,211Withhold
TARGET PORTFOLIO TRUST87,7000 00For
American Century00 081,594Withhold
Bridge Builder Trust73,6260 00For
Voya58,5850 00For
Managed Portfolio Series47,7630 00For
ProShares00 044,862Withhold
ETFis Series Trust I00 042,892Withhold

Showing the 25 largest of 46 asset managers. All 46 are in the interactive database (link above).

3. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 9 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%AGAINST
FOR: 108,778,036AGAINST: 46,997,736

Prior year: 97.6% for (June 16, 2023 meeting) ▼ 27.7 pts

Details: description as filed, official tally, votes by 137 asset managers

Description as filed by funds: APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

LYELL IMMUNOPHARMA INC.’s own tally for this item (“3. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”): 108,778,036 for, 46,997,736 against, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 70% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 46 asset managers voting on “APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at LYELL IMMUNOPHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard011,065,256 00Against
T. Rowe Price05,549,552 00Against
BlackRock04,607,087 00Against
Fidelity03,501,678 00Against
MFS01,469,278 00Against
Charles Schwab01,280,612 00Against
NORTHERN LIGHTS FUND TRUST II0801,016 00Against
QUANTITATIVE MASTER SERIES LLC0334,394 00Against
John Hancock0305,599 00Against
Equitable0247,092 00Against
Lincoln Financial143,90083,215 00Mixed
Global X0221,597 00Against
Invesco0167,700 00Against
Nushares ETF Trust0156,675 00Against
Pacific Life0152,273 00Against
ETF Series Solutions0129,875 00Against
SEI0129,836 00Against
New York Life0112,211 00Against
TARGET PORTFOLIO TRUST087,700 00Against
American Century081,594 00Against
Bridge Builder Trust073,626 00Against
Voya058,585 00Against
Managed Portfolio Series047,763 00Against
ProShares044,862 00Against
ETFis Series Trust I042,892 00Against

Fund voting reports, all 46 managers: 193,866 for, 30,938,479 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 104 asset managers voting on “APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at LYELL IMMUNOPHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Foresite Capital Management IV, LLC8,325,0000 00For
T. Rowe Price06,934,977 00Against
GV Management Company, L.L.C.5,865,1250 00For
Opaleye Management Inc.2,980,0000 00For
GEODE CAPITAL MANAGEMENT, LLC02,689,472 00Against
BlackRock70,5432,303,954 00Against
Fidelity02,226,201 00Against
State Street2,127,50413,625 00For
Charles Schwab01,280,612 00Against
MASSACHUSETTS FINANCIAL SERVICES CO /MA/01,556,226 00Against
BROWN ADVISORY INC01,519,807 00Against
Northern Trust1,073,2952,402 00For
ORBIMED ADVISORS LLC01,012,488 00Against
Invenomic Capital Management LP0866,958 00Against
MELLON INVESTMENTS Corp0741,337 00Against
CANADA PENSION PLAN INVESTMENT BOARD0588,235 00Against
Clarius Group, LLC382,7640 00For
BAILLIE GIFFORD OVERSEAS LTD0293,939 00Against
SEI0262,472 00Against
Vanguard0224,903 00Against
Invesco0218,174 00Against
JPMorgan0185,680 00Against
AllianceBernstein0174,830 00Against
Nuveen0167,744 00Against
BBR PARTNERS, LLC164,0410 00For

Institutional-manager reports, all 104 managers: 21,070,627 for, 25,094,256 against, 382,764 not voted. Showing the 25 largest; every one is in the interactive database (link above).

2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 198,604,866AGAINST: 153,727

Prior year: 100.0% for (June 16, 2023 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.

LYELL IMMUNOPHARMA INC.’s own tally for this item (“2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 198,604,866 for, 153,727 against, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 31,132,345 for.

FOR
FOR: 31,132,345
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING” at LYELL IMMUNOPHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard11,065,2560 00For
T. Rowe Price5,549,5520 00For
BlackRock4,607,0870 00For
Fidelity3,501,6780 00For
MFS1,469,2780 00For
Charles Schwab1,280,6120 00For
NORTHERN LIGHTS FUND TRUST II801,0160 00For
QUANTITATIVE MASTER SERIES LLC334,3940 00For
John Hancock305,5990 00For
Equitable247,0920 00For
Lincoln Financial227,1150 00For
Global X221,5970 00For
Invesco167,7000 00For
Nushares ETF Trust156,6750 00For
Pacific Life152,2730 00For
ETF Series Solutions129,8750 00For
SEI129,8360 00For
New York Life112,2110 00For
TARGET PORTFOLIO TRUST87,7000 00For
American Century81,5940 00For
Bridge Builder Trust73,6260 00For
Voya58,5850 00For
Managed Portfolio Series47,7630 00For
ProShares44,8620 00For
ETFis Series Trust I42,8920 00For

Showing the 25 largest of 46 asset managers. All 46 are in the interactive database (link above).

Largest LYELL IMMUNOPHARMA INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 254,939,222 shares outstanding at the time of that meeting.

Fund voting reports: top LYELL IMMUNOPHARMA INC. shareholders by shares voted on “APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 4.34%
2T. Rowe Price 2.18%
3BlackRock 1.81%
4Fidelity 1.37%
5MFS 0.58%
6Charles Schwab 0.50%
7NORTHERN LIGHTS FUND TRUST II 0.31%
8QUANTITATIVE MASTER SERIES LLC 0.13%
9John Hancock 0.12%
10Equitable 0.10%
Institutional-manager reports: top LYELL IMMUNOPHARMA INC. shareholders by shares voted on “APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE…”, 2023-2024
#Asset manager % of shares outstanding
1Foresite Capital Management IV, LLC 3.27%
2T. Rowe Price 2.72%
3GV Management Company, L.L.C. 2.30%
4Opaleye Management Inc. 1.17%
5GEODE CAPITAL MANAGEMENT, LLC 1.05%
6BlackRock 0.93%
7Fidelity 0.87%
8State Street 0.84%
9Charles Schwab 0.65%
10MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 0.61%

Reported LYELL IMMUNOPHARMA INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

LYELL IMMUNOPHARMA INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Robert Nelsen36,477,716 14.31%Proxy statement (DEF 14A), table as of March 31, 2024
Entities affiliated with ARCH Venture Partners36,412,716 14.28%Proxy statement (DEF 14A), table as of March 31, 2024
Glaxo Group Limited30,253,189 11.87%Proxy statement (DEF 14A), table as of March 31, 2024
Milky Way Investments Group Limited20,162,332 7.91%Proxy statement (DEF 14A), table as of March 31, 2024
Gemini Investments, L.P.15,093,969 5.92%Proxy statement (DEF 14A), table as of March 31, 2024
BlackRock, Inc.14,302,220 5.61%Proxy statement (DEF 14A), table as of March 31, 2024
The Vanguard Group13,604,027 5.34%Schedule 13G, filed February 13, 2024
Richard D. Klausner, M.D.12,002,862 4.71%Proxy statement (DEF 14A), table as of March 31, 2024
T. Rowe Price6,731,477 2.64%Form 13F, quarter ended March 31, 2024
Hans Bishop4,774,844 1.87%Proxy statement (DEF 14A), table as of March 31, 2024

Percentages above are of 254,939,222 shares outstanding, as reported by LYELL IMMUNOPHARMA INC. on its Form 10-Q dated May 2, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At LYELL IMMUNOPHARMA INC.'s shareholder meeting held June 14, 2024, in the 2023-2024 proxy season, 138 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 683 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — FOR was 70% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: LYELL IMMUNOPHARMA INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 14, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LYELL IMMUNOPHARMA INC.’s 10-Q dated May 2, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

LYELL IMMUNOPHARMA INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “LYELL IMMUNOPHARMA (LYEL) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/lyell-immunopharma-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.